Related Experiment Video

Updated: May 22, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders

Tadeusz Robak1, Ewa Robak

  • 1Medical University of Lodz, Department of Hematology, Lodz, Poland. robaktad@csk.umed.lodz.pl

Expert Opinion on Investigational Drugs
|May 23, 2012
PubMed
Abstract

Insights

Tyrosine kinase inhibitors (TKIs) show promise for treating B-cell lymphoid malignancies, autoimmune, and allergic diseases by targeting Bruton's tyrosine kinase (Btk), spleen tyrosine kinase (Syk), and Lyn. Further clinical trials are needed to confirm their efficacy.

Area of Science:

  • Pharmacology
  • Oncology
  • Immunology

Background:

  • Numerous tyrosine kinase inhibitors (TKIs) have emerged for research and clinical trials.
  • TKIs are being investigated for their potential in treating lymphoid malignancies, allergic diseases, and autoimmune disorders.

Purpose of the Study:

  • To summarize recent advancements in the mechanism of action, pharmacology, and clinical activity of TKIs.
  • To review the emerging role of TKIs in lymphoid malignancies, allergic diseases, and autoimmune disorders.

Main Methods:

  • A comprehensive literature review of the MEDLINE database (PubMed) was performed for English articles published between 2000 and January 2012.
  • Searches included specific tyrosine kinase inhibitors (e.g., Btk, Syk, Lyn inhibitors) combined with relevant disease terms.
  • Manual searches of conference proceedings and reference lists of selected articles were also conducted.

Main Results:

  • TKIs, particularly those inhibiting Bruton's tyrosine kinase (Btk), spleen tyrosine kinase (Syk), and Lyn, represent a novel targeted therapy approach.
  • These inhibitors demonstrate potential in managing B-cell lymphoid malignancies, autoimmune conditions, and allergic diseases.

Conclusions:

  • Targeted inhibition of Btk, Syk, and Lyn with TKIs offers a promising therapeutic strategy for B-cell lymphoid malignancies, autoimmune disorders, and allergic diseases.
  • Ongoing and future clinical trials are essential to fully establish the role of TKIs in treating these conditions.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...